Important Therapeutic Targets in Chronic Myelogenous Leukemia

• Published in: Clinical cancer research Vol. 13; no. 4; pp. 1089 - 1097
• Main Authors: Kantarjian, Hagop M., Giles, Francis, Quintás-Cardama, Alfonso, Cortes, Jorge
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 15.02.2007
• Subjects: Antineoplastic agents; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; BCR-ABL; Benzamides; Biological and medical sciences; chronic myeloid leukemia; dasatinib; Fusion Proteins, bcr-abl; Hematologic and hematopoietic diseases; Humans; imatinib; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Medical sciences; nilotinib; Pharmacology. Drug treatments; Piperazines - pharmacology; Piperazines - therapeutic use; Protein Kinase Inhibitors - pharmacology; Protein Kinase Inhibitors - therapeutic use; Protein-Tyrosine Kinases - antagonists & inhibitors; Protein-Tyrosine Kinases - metabolism; Pyrimidines - pharmacology; Pyrimidines - therapeutic use; Myeloproliferative syndrome; Malignant hemopathy; Targeting; Targeted therapy; Chronic myelocytic leukemia

Purpose: Review the state-of-art knowledge of the biology and therapy of chronic myelogenous leukemia (CML). Experimental Design: A review of the literature was undertaken to summarize current information on the pathophysiology of CML and to update data of imatinib mesylate therapy, mechanisms of re...